Coherus Oncology publishes presentation on tagmokitug interim clinical data
CHRS•Coherus Oncology published interim clinical data for tagmokitug in esophageal cancer. First-line treatment with toripalimab and chemotherapy had a 75% confirmed response rate among eight evaluable patients; second-line treatment at 700 mg showed median progression-free survival of 5.5 months, with data still immature.
1. Interim clinical results
Coherus Oncology published a presentation reporting interim results for tagmokitug in esophageal cancer. First-line tagmokitug with toripalimab and chemotherapy achieved a 75% confirmed response rate among eight evaluable patients. In second-line treatment at 700 mg, median progression-free survival was 5.5 months; the data remain immature.
2. Safety and development plans
Grade 3 or higher adverse events related to tagmokitug affected 20% of first-line patients and 23.5% of second-line patients. Coherus plans to expand first-line enrollment to 30–40 patients and pursue parallel first- and second-line development targeting global pivotal trials.
